Avtor/Urednik		Lavrič, Alenka; Urbančič, Mojca; Kraut, Aleksandra; Sevšek, Davorin; Jaki, Polona
Naslov		Zdravljenje horoidalne neovaskularizacije pri visoko kratkovidnih očeh
Prevedeni naslov		Treatment of choroidal neovascularisation in highly myopic eyes
Tip		članek
Vir		Zdrav Vestn
Vol. in št.		Letnik 81, št. Suppl
Leto izdaje		2012
Obseg		str. I-67-72
Jezik		slo
Abstrakt		Background: The aim of this study was to examine the effectiveness (visual outcome) of photodynamic therapy with verteporfin (PDT) and intravitreal anti-VEGF therapy for the treatment of choroidal neovascularisation secondary to pathologic myopia. Methods: A retrospective study of choroidal neovascularisation in highly myopic patients was undertaken at the Eye Hospital Ljubljana (from 2004 to 2010). The main outcome measures were: spherical equivalent, age at onset of CNV, composition and location of CNV, visual acuity before treatment, treatment type (PDT, intravitreal anti-VEGF injections, combination of both treatments), visual acuity after treatment andtreatment-related complications. Results: Fifty-nine eyes of 59 patients (7men and 52 women) with myopic CNV were enrolled in the study. The mean age of the patients was 59.7 (range 26-83) years and the spherical equivalent refractive error was - 10.2 D (range - 6.0 D to - 20.0 D). Twenty-four eyes were treated with PDT, 9 with PDT and anti-VEGF, and 26 eyes with anti-VEGF injections alone. The followup period was 21.5 months (range 6 months-6 years). The patients treated with anti-VEGF injections had a better final best-corrected visual acuity than PDT treated patients. No systemic side effects were noted. Conclusions: Intravitreal anti-VEGF injections are an effective therapy for sub- and juxtafoveal myopic CNV.
Izvleček		Izhodišča: Namen študije je bil proučiti učinkovitost (vpliv na vid) fotodinamične terapije z verteporfinom (PDT) in zdravljenja z zaviralci rastnega dejavnika za endotelj žil (anti-VEGF) pri zdravljenju horoidalne neovaskularizacije (CNV) pri patološki kratkovidnosti. Metode: Retrospektivni pregled zdravljenja visoko kratkovidnih bolnikov s CNV na Očesni kliniki v Ljubljani (od leta 2004 do leta 2010). Ocenjevali smo: sferičen ekvivalent, starost ob pojavu CNV, vrsto in lego CNV v makuli, vidno ostrino pred zdravljenjem, vrsto zdravljenja (PDT, intravitrealne injekcije anti-VEGF, kombinacija obeh zdravljenj), vidno ostrino po zdravljenju in zaplete zdravljenja. Rezultati: V študijo smo vključili devetinpetdeset oči z miopičnoCNV pri 59 (7 moških in 52 žensk) zaporedno zdravljenih miopičnih bolnikih. Povprečna starost bolnikov je bila 59,7 let (razpon med 26 in 83 leti) in sferičen ekvivalent refrakcijske napake je bil -10,2 D (razpon med -6,0 D in -20,0 D). 24 oči smo zdravili s PDT, 9 s PDT in anti-VEGF ter 26 očile z anti-VEGF. Obdobje sledenja je bilo 21,5 mesecev (razpon med 6 meseci in 6 leti). Bolniki zdravljeni z anti- -VEGF so imeli boljšo končno vidno ostrino kot bolniki zdravljeni s PDT. Sistemskih stranskih učinkov nismo opazili. Zaključki: Intravitrealne injekcije anti-VEGF so učinkovito zdravljenje za sub- in jukstafovealne miopične CNV.